PA21259, sbir, phase i, improving t cell responses in vaccines: prediction and validation using existing databases, immunoinformatics and in vitro assays
Ended Formula Grant Awarded Last action
- Award ID
- R43IP001225
- Recipient
-
Epivax Inc. UEI NLAVQM513F18
- Awarding agency
-
Office of Financial Resources
Centers for Disease Control and Prevention, Department of Health and Human Services
- Obligated
- $571,681
Award facts
- Assistance listing
- 93.283 Centers for Disease Control and Prevention Investigations and Technical Assistance
- Completion date
- Originally
- Funding agency
- Office of the Director Centers for Disease Control and Prevention, Department of Health and Human Services
- Place of performance
- Rhode Island, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$28,179 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $299,930 | |
| Original award | $299,930 |
Quick answers
Who received award R43IP001225?
R43IP001225 was awarded to Epivax Inc. by Office of Financial Resources (Centers for Disease Control and Prevention) on September 30, 2023.
How much is award R43IP001225 worth?
$571,681 has been obligated on R43IP001225.
Which agency awarded R43IP001225?
Office of Financial Resources (Centers for Disease Control and Prevention) awarded R43IP001225, with funding from Office of the Director (Centers for Disease Control and Prevention).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award